- Home
- TGB vs KALV Comparison
TGB vs KALV Comparison
Compare TGB & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGB
- KALV
- Stock Information
- Founded
- TGB 1966
- KALV N/A
- Country
- TGB Canada
- KALV United States
- Employees
- TGB N/A
- KALV N/A
- Industry
- TGB Precious Metals
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- TGB Basic Materials
- KALV Health Care
- Exchange
- TGB Nasdaq
- KALV Nasdaq
- Market Cap
- TGB 698.1M
- KALV 642.3M
- IPO Year
- TGB N/A
- KALV N/A
- Fundamental
- Price
- TGB $3.62
- KALV $14.31
- Analyst Decision
- TGB
- KALV Strong Buy
- Analyst Count
- TGB 0
- KALV 9
- Target Price
- TGB N/A
- KALV $26.29
- AVG Volume (30 Days)
- TGB 11.5M
- KALV 2.0M
- Earning Date
- TGB 07-30-2025
- KALV 07-10-2025
- Dividend Yield
- TGB N/A
- KALV N/A
- EPS Growth
- TGB N/A
- KALV N/A
- EPS
- TGB N/A
- KALV N/A
- Revenue
- TGB $417,640,101.00
- KALV N/A
- Revenue This Year
- TGB $22.13
- KALV N/A
- Revenue Next Year
- TGB $36.13
- KALV $347.19
- P/E Ratio
- TGB N/A
- KALV N/A
- Revenue Growth
- TGB 7.89
- KALV N/A
- 52 Week Low
- TGB $1.67
- KALV $7.30
- 52 Week High
- TGB $3.68
- KALV $16.32
- Technical
- Relative Strength Index (RSI)
- TGB 71.05
- KALV 58.58
- Support Level
- TGB $3.15
- KALV $11.10
- Resistance Level
- TGB $3.68
- KALV $16.32
- Average True Range (ATR)
- TGB 0.18
- KALV 1.10
- MACD
- TGB 0.03
- KALV 0.36
- Stochastic Oscillator
- TGB 90.66
- KALV 68.95
About TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.